AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 172 min read$BIAF

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant - bioAffinity Technologies (NASDAQ

BioAffinity Technologies (NASDAQ:BIAF) shares rose 50.47% to $8.05 Thursday after receiving a Hong Kong patent for its CyPath Lung diagnostic. The patent complements a 2025 patent in China, covering a region with high lung cancer incidence. CyPath Lung has shown strong clinical performance, with 92% sensitivity and 87% specificity in trials. The company's warrants (NASDAQ:BIAFW) also gained nearly 20%.

Original reporting
benzinga.com
Published Sep 17, 2026, 7:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 7:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$BIAF
Bullish
high confidence
Mentioned
$BIAF
Relevance
7/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$BIAFBullishMed
01

Why it matters

The dual‑region IP coverage is expected to solidify market positioning and could translate into higher sales and partnership opportunities.

02

Market read

The patent grant is a catalyst for a sharp price increase and may influence investor sentiment toward similar biotech firms.

03

What to watch

Potential competition from other liquid‑biopsy platforms and regulatory hurdles in other jurisdictions.

Relevance 7/10Novelty 8/10Timing: Thursday afternoon

Background

BioAffinity Technologies (NASDAQ:BIAF) develops non‑invasive lung cancer diagnostics. The company recently secured a Chinese patent and now adds Hong Kong protection.

Company-level read

Ticker impact

$BIAFBullishHigh confidence
Context

BioAffinity Technologies shares jumped 50% after the Hong Kong patent for its CyPath Lung diagnostic was granted, a fresh catalyst driving the surge.

Expected impact

upward pressure as investors buy on the news

Evidence & confidence

New, material IP protection in a key region directly triggers a large intraday price move; similar biotech patent approvals have historically led to sustained upside.

Market effects

Sector

Strengthens the lung‑diagnostics niche and may boost related biotech peers with similar IP strategies.

Regional

Highlights Hong Kong/China as a growing market for advanced diagnostics, potentially attracting investor interest in Asian biotech listings.

Global

Adds to the narrative of expanding non‑invasive cancer diagnostics worldwide.

Counterpoint

What could challenge this read

The rally may be over‑optimistic if commercialization timelines or reimbursement approvals lag behind the patent grant.

Key entities

  • company
    BioAffinity Technologies Inc.

    Developer of the CyPath Lung diagnostic platform.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 8
$BIAFLow

bioAffinity Technologies, Inc. (BIAF): Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia

bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia

SEC EDGAR 8-K2 min
SEP 17
$BIAFMed

BIAF stock jumps on Hong Kong patent news, with recent low-float dynamics likely adding to volatility

bioAffinity Technologies (BIAF) shares rose 74.0% after Hong Kong granted a patent for its CyPath Lung lung-cancer detection technology, strengthening its IP position in Asia. The company's recent reverse stock split, reducing shares outstanding to 592,373, may have amplified the volatility. Several institutional investors adjusted their positions in Q2 2026, with notable additions from SABBY MANAGEMENT and BLACKROCK.

quiverquant.com2 min
SEP 5
$BIAFMedAI 8/10

bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right?

bioAffinity Technologies (BIAF) rose 47.95% after announcing its AI-based lung-cancer surveillance tool, CyPath Lung, and a 1-for-15 reverse stock split. Q2 test volume surged 216% YoY, but the company reported a $3.4M net loss and $2.4M cash. Clinical study results showed 92% sensitivity and 88% accuracy. The company faces challenges in scaling revenue and managing dilution risks.

insidermonkey.com3 min
SEP 3
$BIAFHigh

Why is bioAffinity Technologies stock surging today?

bioAffinity Technologies (BIAF) stock surged 39.4% in pre-market trading after announcing its CyPath® Lung test can now monitor lung cancer recurrence, expanding its commercial use. The company's small float, due to a recent reverse stock split, amplified the price movement. The broader market showed no significant impact.

investing.com2 min
SEP 2
$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

rttnews.com2 min